Zhejiang Taimei Medical Technology Co., Ltd. (2576) convened its first extraordinary general meeting for 2026 on February 14, 2026. According to the announcement, shareholders holding 367.90 million shares—equivalent to 65.28% of the total 563.78 million issued shares—were present in person or by proxy. Among these shares, 0.17 million were treasury shares with no voting rights exercised.

All resolutions set out in the meeting notice were passed. Resolution 1, concerning the adoption of the 2026 H Share Award Scheme with a scheme mandate limit of 10% of total issued H Shares (excluding treasury shares), was approved as a special resolution. Ordinary resolutions 2 through 7, including the conditional award grants to certain directors and senior management, were likewise passed. It was disclosed that 179.42 million shares held by one of the executive directors and his associates abstained from voting on the relevant award grant resolutions.

The document also clarified that specific performance targets were not mandated under the 2026 H Share Award Scheme, noting that each selected participant may contribute differently to the long-term growth of the Group and that the purpose of the scheme is to encourage and recognize significant contributions. The announcement confirmed that all directors of Zhejiang Taimei Medical participated in the meeting, either in person or through electronic means.